Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Revenue (2016 - 2025)

Tg Therapeutics has reported Revenue over the past 10 years, most recently at $192.6 million for Q4 2025.

  • Quarterly results put Revenue at $192.6 million for Q4 2025, up 78.0% from a year ago — trailing twelve months through Dec 2025 was $616.3 million (up 87.32% YoY), and the annual figure for FY2025 was $616.3 million, up 87.32%.
  • Revenue for Q4 2025 was $192.6 million at Tg Therapeutics, up from $161.7 million in the prior quarter.
  • Over the last five years, Revenue for TGTX hit a ceiling of $192.6 million in Q4 2025 and a floor of $80000.0 in Q4 2022.
  • Median Revenue over the past 5 years was $30.0 million (2023), compared with a mean of $59.4 million.
  • Biggest five-year swings in Revenue: plummeted 96.55% in 2022 and later surged 176298.94% in 2023.
  • Tg Therapeutics' Revenue stood at $2.3 million in 2021, then plummeted by 96.55% to $80000.0 in 2022, then soared by 54863.75% to $44.0 million in 2023, then soared by 146.04% to $108.2 million in 2024, then surged by 78.0% to $192.6 million in 2025.
  • The last three reported values for Revenue were $192.6 million (Q4 2025), $161.7 million (Q3 2025), and $141.1 million (Q2 2025) per Business Quant data.